Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer
December 07 2020 - 4:30PM
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage
company developing transformative therapies for the treatment of
cancer and rare diseases with significant unmet needs, today
announced the promotion of Jacqueline (Jackie) Zummo, Ph.D., MPH,
MBA from Senior Vice President, Research and Development Operations
to Chief Scientific Operations Officer.
“As co-founder of Protara, Jackie has played a
pivotal role in much of the Company’s success to date,” said Jesse
Shefferman, Chief Executive Officer
of Protara Therapeutics. “I look forward to
working with Jackie in her new role, where her vast expertise and
commitment to patients will continue to make an important impact as
we execute our strategy, including advancing our lead program,
TARA-002, for the treatment of non-muscle invasive bladder cancer
and lymphatic malformations.”
“In just a few short years since the Company’s
inception, Protara has rapidly evolved into the remarkable
organization it is today, with several exciting programs underway
that we believe have the potential to address key areas of unmet
need,” said Dr. Zummo. “I look forward to continuing to contribute
to our growth as we advance our mission of bringing transformative
therapies to patients with cancer and other rare diseases.”
Dr. Zummo has over 15 years of experience in
senior leadership roles in the biopharma industry, with a strong
track record of streamlining clinical development programs and
driving successful regulatory outcomes. She co-founded Protara in
2017, serving as Vice President, Clinical Research and Medical
Affairs before being promoted to Senior Vice President, Research
and Development Operations in 2019. Prior to joining Protara, Dr.
Zummo was Assistant Vice President, Medical Affairs at Vyera
Pharmaceuticals, LLC, with prior clinical development, operations
and medical affairs roles at Alkermes, Inc., Sunovion
Pharmaceuticals Inc. and Wyeth Pharmaceuticals Inc. (later acquired
by Pfizer, Inc.). In addition to her work in clinical development,
Dr. Zummo has been instrumental in the launch and commercialization
of multiple products, including Pristiq, Aptiom, Latuda and
Aristada. She has extensive experience in building strategic
relationships with Key Opinion Leads, generating Health Economics
and Outcomes Research analytics, and communicating real-world value
to managed care organizations.
About Protara Therapeutics, Inc.
Protara is committed to identifying and
advancing transformative therapies for people with cancer and rare
diseases with limited treatment options. Protara’s portfolio
includes its lead program, TARA-002, an investigational cell-based
therapy being developed for the treatment of non-muscle invasive
bladder cancer and lymphatic malformations, and IV Choline
Chloride, an investigational phospholipid substrate replacement
therapy for the treatment of intestinal failure-associated liver
disease. For more information, visit www.protaratx.com.
Forward-Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are "forward
looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. Protara may, in some cases, use
terms such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “designed,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words or expressions referencing future events, conditions or
circumstances that convey uncertainty of future events or outcomes
to identify these forward-looking statements. Such forward-looking
statements include but are not limited to, statements regarding
Protara’s intentions, beliefs, projections, outlook, analyses or
current expectations concerning, among other things: statements
regarding Protara’s business strategy; Dr. Zummo’s expected role on
our executive team and in driving the growth of Protara’s business;
and the contribution of Dr. Zummo’s experience and past
achievements in helping us achieve our strategic objectives,
including the advancement of our programs. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Factors that contribute to the uncertain nature of the
forward-looking statements include risks and uncertainties
associated with: Protara’s development programs, including the
initiation and completion of non-clinical studies and clinical
trials and the timing of required filings with the FDA and other
regulatory agencies; the impact of the COVID-19 pandemic on
Protara’s business and the global economy; general market
conditions; changes in the competitive landscape; changes in
Protara’s strategic and commercial plans; Protara’s ability to
obtain sufficient financing to fund its strategic plans and
commercialization efforts; the loss of key members of management;
and the risks and uncertainties associated with Protara’s business
and financial condition in general, including the risks and
uncertainties described more fully under the caption "Risk Factors"
and elsewhere in Protara's filings and reports with the United
States Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management's
assumptions and estimates as of such date. Protara undertakes no
obligation to update any forward-looking statements, whether as a
result of the receipt of new information, the occurrence of future
events or otherwise, except as required by law.
Company Contact:
Justine O'MalleyProtara
TherapeuticsJustine.OMalley@protaratx.com646-817-2836
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jul 2023 to Jul 2024